Literature DB >> 17392503

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma.

Christine Damm-Welk1, Kerstin Busch, Birgit Burkhardt, Jutta Schieferstein, Susanne Viehmann, Ilske Oschlies, Wolfram Klapper, Martin Zimmermann, Jochen Harbott, Alfred Reiter, Willi Woessmann.   

Abstract

Clinical and histopathological characteristics have limited prognostic value for children with anaplastic large-cell lymphoma (ALCL). We evaluated the presence, extent, and prognostic impact of circulating tumor cells in bone marrow (BM) and peripheral blood (PB) of children and adolescents with NPM-ALK-positive ALCL at diagnosis using qualitative and quantitative polymerase chain reaction (PCR) for NPM-ALK. Numbers of NPM-ALK transcripts were normalized to 10(4) copies ABL (NCNs). BM was analyzed from 80 patients and PB from 52. BM was positive for NPM-ALK in 47.5% of patients, and positivity was significantly correlated with clinical stage, mediastinal or visceral involvement, microscopic BM involvement, and histologic subtype. Qualitative and quantitative PCR results in BM and PB strongly correlated. BM PCR was associated with the cumulative incidence of relapses (CI-Rs): CI-R was 50% +/- 10% for 38 PCR-positive and 15% +/- 7% for 42 PCR-negative patients (P < .001). Sixteen patients with more than 10 NCNs NPM-ALK in BM had a CI-R of 71% +/- 14% compared with a CI-R of 18% +/- 6% for 59 patients with 10 or fewer NCNs (P < .001). PB PCR results led to a similar grouping. Thus, quantitative PCR in BM or PB allows identification of 20% of patients experiencing 60% of all relapses with an event-free survival of 20%.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392503     DOI: 10.1182/blood-2007-02-066852

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study.

Authors:  Ilske Oschlies; Jasmin Lisfeld; Laurence Lamant; Atsuko Nakazawa; Emanuele S G d'Amore; Ulrika Hansson; Konnie Hebeda; Ingrid Simonitsch-Klupp; Jadwiga Maldyk; Leonhard Müllauer; Marianne Tinguely; Markus Stücker; Marie-Cecile Ledeley; Reiner Siebert; Alfred Reiter; Laurence Brugières; Wolfram Klapper; Wilhelm Woessmann
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group.

Authors:  Sarah Alexander; Jacqueline M Kraveka; Sheila Weitzman; Eric Lowe; Lynette Smith; James C Lynch; Myron Chang; Marsha C Kinney; Sherrie L Perkins; Joseph Laver; Thomas G Gross; Howard Weinstein
Journal:  Pediatr Blood Cancer       Date:  2014-08-23       Impact factor: 3.167

Review 3.  [Malignant lymphomas in children and adolescents. Practical knowledge for diagnosis].

Authors:  I Oschlies; W Klapper
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

Review 4.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

5.  Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

Authors:  Yael P Mossé; Stephan D Voss; Megan S Lim; Delphine Rolland; Charles G Minard; Elizabeth Fox; Peter Adamson; Keith Wilner; Susan M Blaney; Brenda J Weigel
Journal:  J Clin Oncol       Date:  2017-08-08       Impact factor: 44.544

6.  Revised International Pediatric Non-Hodgkin Lymphoma Staging System.

Authors:  Angelo Rosolen; Sherrie L Perkins; C Ross Pinkerton; R Paul Guillerman; John T Sandlund; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

7.  International Pediatric Non-Hodgkin Lymphoma Response Criteria.

Authors:  John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

8.  Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.

Authors:  Eric J Lowe; Richard Sposto; Sherrie L Perkins; Thomas G Gross; Jonathan Finlay; David Zwick; Minnie Abromowitch
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

9.  Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Dmitriy Abramov; Ilske Oschlies; Martin Zimmermann; Dmitriy Konovalov; Christine Damm-Welk; Wilhelm Wössmann; Wolfram Klapper
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Authors:  Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.